About Singulex
Singulex is a company based in Alameda (United States) founded in 1997. Singulex has raised $140.94 million across 16 funding rounds from investors including SVB, Grifols and HHS. The company has 236 employees as of December 31, 2017. Singulex offers products and services including Sgx Clarity System. Singulex operates in a competitive market with competitors including Metabolon, Maze Therapeutics, Seer, Alector and NanoCellect Biomedical, among others.
- Headquarter Alameda, United States
- Employees 236 as on 31 Dec, 2017
-
Sectors
Healthcare
-
Phone
Locked
-
Website
Locked
-
Social
Locked
-
Annual Revenue
Not available
-
Net Profit
Not available
-
EBITDA
Not available
-
Total Equity Funding
$140.94 M (USD)
in 16 rounds
-
Latest Funding Round
$50 M (USD), Debt – Conventional
Apr 17, 2017
-
Investors
SVB
& 10 more
-
Employee Count
236
as on Dec 31, 2017
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Products & Services of Singulex
Singulex offers a comprehensive portfolio of products and services, including Sgx Clarity System.
Ultra-sensitive platform for detecting low-abundance biomarkers in healthcare
Funding Insights of Singulex
Singulex has successfully raised a total of $140.94M across 16 strategic funding rounds. The most recent funding activity was a Debt – Conventional round of $50 million completed in April 2017. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
Investors in Singulex
Singulex has secured backing from 11 investors, including venture fund and institutional investors. Prominent investors backing the company include SVB, Grifols and HHS.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
|
Health-tech companies are targeted for venture capital investments.
|
Locked | Locked | Locked | |
|
Venture debt firm focused on the life sciences sector
|
Locked | Locked | Locked | |
|
Health-focused venture capital investments are made in US sectors.
|
Locked | Locked | Locked |
Investor details for Singulex
Investor domains, locations, round participation, and complete history require an active premium plan.
- Investor domains
- Investor locations
- Funding rounds
- Participation history
Verified entity values are shown only after access is granted.
Investments & Acquisitions by Singulex
Investment portfolio details for Singulex
Portfolio company identities, transaction dates, round details, and investment values require an active premium plan.
- Portfolio identities
- Transaction dates
- Round details
- Investment values
Verified entity values are shown only after access is granted.
Financial Statements - Singulex
Detailed financials for Singulex
Historical revenue, profit, statement rows, ratios, and trend charts require an active premium plan.
- Historical revenue
- Profit trends
- Statement rows
- Financial ratios
Verified entity values are shown only after access is granted.
Singulex Comparisons
Peer comparison for Singulex
Named peer metrics, headcount, funding, location, and side-by-side benchmarks require an active premium plan.
- Named peers
- Headcount comparison
- Funding comparison
- Operating benchmarks
Verified entity values are shown only after access is granted.
Competitors of Singulex
Singulex operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Metabolon, Maze Therapeutics, Seer, Alector and NanoCellect Biomedical, among others.
| Company Name | Domain | Founded year | HQ Location | Description |
|---|---|---|---|---|
| Locked | Locked | Locked |
Solutions for biomarker discovery and diagnostic testing are provided.
|
|
| Locked | Locked | Locked |
Genetic biomarkers are developed for neurological, metabolic, and renal diseases.
|
|
| Locked | Locked | Locked |
Proteomics platform developed for early cancer and neurological disease detection.
|
|
| Locked | Locked | Locked |
Immuno-modulatory therapies for dementia and neurodegenerative disorders are developed.
|
|
| Locked | Locked | Locked |
Develops flow cytometry and cell sorting technology
|
|
| Locked | Locked | Locked |
Single-cell data is analyzed via AI for biomarker discovery.
|
Detailed competitors of Singulex
Competitor domains, locations, full profiles, and operating metrics require an active premium plan.
- Domains and locations
- Full company profiles
- Operating metrics
- Competitive positioning
Verified entity values are shown only after access is granted.
Latest news on Singulex
Complete news archive for Singulex
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Singulex
Singulex was founded in 1997 and raised its 1st funding round 5 years after it was founded.
Singulex is headquartered in Alameda, United States. It is registered at Alameda, California, United States.
Guido Baechler is the current CEO of Singulex.
Singulex is a funded company, having raised a total of $140.94M across 16 funding rounds to date.
As of Dec 31, 2017, the latest employee count at Singulex is 236.
Singulex was founded in 1997 in Alameda, United States, and operates in the biotechnology sector focused on cardiodiagnostics. Single-molecule counting instruments and biomarker research are developed and commercialized for cardiovascular monitoring. Immunoassay solutions, lab testing services, and the Clarity System for automated in vitro analysis are provided to support disease treatment, health management, and therapeutic development.
Singulex's top competitors include Alector, Maze Therapeutics and Metabolon.
Singulex offers Sgx Clarity System.
Singulex has 11 investors. Key investors include SVB, Grifols, HHS, Orbimed, and Western Alliance Bank.